CA2184493A1 - Methods and compositions useful for inhibition of angiogenesis - Google Patents

Methods and compositions useful for inhibition of angiogenesis

Info

Publication number
CA2184493A1
CA2184493A1 CA002184493A CA2184493A CA2184493A1 CA 2184493 A1 CA2184493 A1 CA 2184493A1 CA 002184493 A CA002184493 A CA 002184493A CA 2184493 A CA2184493 A CA 2184493A CA 2184493 A1 CA2184493 A1 CA 2184493A1
Authority
CA
Canada
Prior art keywords
tissue
angiogenesis
beta
alpha
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002184493A
Other languages
French (fr)
Other versions
CA2184493C (en
Inventor
Peter Brooks
David A. Cheresh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22783992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2184493(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2184493A1 publication Critical patent/CA2184493A1/en
Application granted granted Critical
Publication of CA2184493C publication Critical patent/CA2184493C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin .alpha.v.beta.3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing .alpha.v.beta.3 antagonists.

Claims (54)

  1. What Is Claimed Is:
    l. A method for inhibiting angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an .alpha.v.beta.3 antagonist.
  2. 2. The method of claim 1 wherein said .alpha.v.beta.3 antagonist inhibits binding of fibrinogen to .alpha.v.beta.3 but does not substantially inhibit binding of fibrinogen to .alpha.IIb.beta.3 or .alpha.v.beta.1.
  3. 3. The method of claim 1 wherein said .alpha.v.beta.3 antagonist is a monoclonal antibody immunospecific for .alpha.v.beta.3.
  4. 4. The method of claim 3 wherein said monoclonal antibody has the immunoreaction characteristics of the monoclonal antibody LM609 (ATCC HB 9537).
  5. 5. The method of claim 1 wherein said .alpha.v.beta.3 antagonist is an RGD-containing polypeptide.
  6. 6. The method of claim 5 wherein said polypeptide is selected from the group consisting of c-(GrGDFV) (SEQ ID NO 4), c-(RGDfV) (SEQ ID NO
    5), c-(RGDEv) (SEQ ID NO 7), and YTAECKPQVTRGDVF
    (SEQ ID NO 8), and a salt thereof.
  7. 7. The method of claim 6 wherein said salt is hydrochloride or trifluoroacetate.
  8. 3. The method of claim 1 wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.
  9. 9. The method of claim 8 wherein said tissue is arthritic.
  10. 10. The method of claim 9 wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.
  11. 11. The method of claim 1 wherein said tissue is the retinal tissue of a patient with diabetic retinopathy and said angiogenesis is retinal angiogenesis .
  12. 12. The method of claim 1 wherein said tissue is a hemangioma.
  13. 13. The method of claim 1 wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.
  14. 14. The method of claim 1 wherein said angiogenesis-inhibiting amount is from about 2 uM
    to 5 mM.
  15. 15. The method of claim 1 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration .
  16. 16. The method of claim 1 wherein said administering is conducted in conjunction with chemotherapy .
  17. 17. The method of claim 1 wherein said administering comprises a single dose intravenously .
  18. 18. A method for regression of established tumor in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an .alpha.v.beta.3 antagonist.
  19. 19. The method of claim 18 wherein said .alpha.v.beta.3 antagonist inhibits binding of fibrinogen to .alpha.v.beta.3 but does not substantially inhibit binding of fibrinogen to .alpha.IIb.beta.3 or .alpha.v.beta.1.
  20. 20. The method of claim 18 wherein said .alpha.v.beta.3 antagonist is a monoclonal antibody immunospecific for .alpha.v.beta.3.
  21. 21. The method of claim 20 wherein said monoclonal antibody has the immunoreaction characteristics of the monoclonal antibody LM609 (ATCC HB 9537).
  22. 22. The method of claim 18 wherein said .alpha.v.beta.3 antagonist is an RGD-containing polypeptide.
  23. 23. The method of claim 22 wherein said polypeptide is selected from the group consisting of c-(GrGDFV) (SEQ ID NO 4), c-(RGDfV) (SEQ ID NO

    5), c-(RGDFv) (SEQ ID NO 7), and YTAECKPQVTRGDVF
    (SED ID NO 8), and a salt thereof.
  24. 24. The method of claim 23 wherein said salt is hydrochloride or trifluoroacetate.
  25. 25. The method of claim 18 wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis
  26. 26. The method of claim 25 wherein said tissue is arthritic.
  27. 27. The method of claim 26 wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.
  28. 28. The method of claim 18 wherein said tissue is the retinal tissue of a patient with diabetic retinopathy and said angiogenesis is retinal angiogenesis.
  29. 29. The method of claim 18 wherein said tissue is a hemangioma.
  30. 30, The method of claim 18 wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.
  31. 31. The method of claim 18 wherein said angiogenesis-inhibiting amount is from about 2 uM
    to 5 mM.
  32. 32. The method of claim 18 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.
  33. 33. The method of claim 18 wherein said administering is conducted in conjunction with chemotherapy.
  34. 34. The method of claim 18 wherein said administering comprises a single dose intravenously.
  35. 35. The method of claim 18 wherein said regression occurs 7 days following administration of said angiogenesis-inhibiting antagonist.
  36. 36. A method of inducing apoptosis in neo-vasculature in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an .alpha.v.beta.3 antagonist.
  37. 37. The method of claim 36 wherein said .alpha.v.beta.3 antagonist inhibits binding of fibrinogen to .alpha.v.beta.3 but does not substantially inhibit binding of fibrinogen to .alpha.IIb.beta.3 or .alpha.v.beta.1.
  38. 38. The method of claim 36 wherein said .alpha.v.beta.3 antagonist is a monoclonal antibody immunospecific for .alpha.v.beta.3.
  39. 39. The method of claim 38 wherein said monoclonal antibody has the immunoreaction characteristics of the monoclonal antibody LM609 (ATCC HB 9537).
  40. 40. The method of claim 36 wherein said .alpha.v.beta.3 antagonist is an RGD-containing polypeptide.
  41. 41. The method of claim 40 wherein said polypeptide is selected from the group consisting of c-(GrGDFV) (SEQ ID NO 4), c-(RGDfV) (SEQ ID NO 5), c-(RGDFv) (SEQ ID NO 7), and YTAECKPQVTRGDVF (SEQ
    ID NO 8), and a salt thereof .
  42. 42. The method of claim 41 wherein said salt is hydrochloride or trifluoroacetate.
  43. 43. The method of claim 36 wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.
  44. 44. The method of claim 43 wherein said tissue is arthritic.
  45. 45. The method of claim 44 wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.
  46. 46. The method of claim 36 wherein said tissue is the retinal tissue of a patient with diabetic retillopathy and said angiogenesis is retinal angiogenesis.
  47. 47. The method of claim 36 wherein said tissue is a hemangioma.
  48. 48. The method of claim 36 wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.
  49. 49. The method of claim 36 wherein said angiogenesis-inhibiting amount is from about 2 uM
    to 5 mM.
  50. 50. The method of claim 36 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.
  51. 51. The method of claim 36 wherein said administering is conducted in conjunction with chemotherapy.
  52. 52. The method of claim 36 wherein said administering comprises a single dose intravenously.
  53. 53. The method of claim 36 wherein said apoptosis occurs at least 48 hours following administration of said angiogenesis-inhibiting antagonist.
  54. 54. The method of claim 1 wherein said tissue is a coronary artery at risk of restenosis following coronary angioplasty.
CA2184493A 1994-03-18 1995-03-09 Methods and compositions useful for inhibition of angiogenesis Expired - Fee Related CA2184493C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/210,715 1994-03-18
US08/210,715 US5753230A (en) 1994-03-18 1994-03-18 Methods and compositions useful for inhibition of angiogenesis
US08/366,665 1994-12-30
US08/366,665 US5766591A (en) 1994-03-18 1994-12-30 Methods and compositions useful for inhibition of angiogenesis
PCT/US1995/003035 WO1995025543A1 (en) 1994-03-18 1995-03-09 Methods and compositions useful for inhibition of angiogenesis

Publications (2)

Publication Number Publication Date
CA2184493A1 true CA2184493A1 (en) 1995-09-28
CA2184493C CA2184493C (en) 2010-05-11

Family

ID=22783992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2184493A Expired - Fee Related CA2184493C (en) 1994-03-18 1995-03-09 Methods and compositions useful for inhibition of angiogenesis

Country Status (25)

Country Link
US (7) US5753230A (en)
EP (3) EP0754059B2 (en)
JP (2) JP4268222B2 (en)
KR (1) KR100327081B1 (en)
CN (1) CN1161152C (en)
AT (3) ATE490784T1 (en)
AU (1) AU709645B2 (en)
CA (1) CA2184493C (en)
CZ (1) CZ294650B6 (en)
DE (2) DE69532279T3 (en)
DK (3) DK0754059T4 (en)
ES (3) ES2355074T3 (en)
FI (1) FI121916B (en)
HK (1) HK1013960A1 (en)
HU (1) HU221988B1 (en)
MX (1) MX9604145A (en)
NO (1) NO322441B1 (en)
NZ (3) NZ283022A (en)
PT (2) PT1468695E (en)
RU (1) RU2162712C2 (en)
SI (1) SI0754059T2 (en)
SK (1) SK284586B6 (en)
UA (1) UA44729C2 (en)
WO (1) WO1995025543A1 (en)
ZA (1) ZA952214B (en)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4310643A1 (en) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclic adhesion inhibitors
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6949511B1 (en) 1994-04-26 2005-09-27 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
PT719859E (en) * 1994-12-20 2003-11-28 Merck Patent Gmbh ANTI-ALPHA MONOCLONAL ANTIBODY V-INTEGRINA
US6440729B1 (en) * 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
WO1997006791A1 (en) * 1995-08-14 1997-02-27 The Scripps Research Institute METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
ATE203234T1 (en) 1995-08-30 2001-08-15 Searle & Co META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINOBENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
ATE248912T1 (en) 1995-10-23 2003-09-15 Childrens Medical Center THERAPEUTIC ANTIANGIOGENIC COMPOSITIONS AND METHODS
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
US6589755B1 (en) * 1996-08-15 2003-07-08 Novartis Ag Assay for quantifying arthritic conditions
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
DE69739295D1 (en) * 1996-12-09 2009-04-23 Merck Patent Gmbh Soluble, recombinant alphaV beta3 adhesion receptor
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
DE69828154T2 (en) * 1997-03-12 2005-06-23 Smithkline Beecham Corp. ANTI-ALPHAVBETA3 HUMANIZED MONOCLONAL ANTIBODIES
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5994388A (en) * 1997-03-18 1999-11-30 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
AU6569198A (en) * 1997-03-19 1998-10-12 Lucid Technologies, Inc. Cellular surgery utilizing confocal microscopy
US6193968B1 (en) * 1997-04-11 2001-02-27 The Burnham Institute Methods for using anti-αvβ3 integrin antibody
PT973550E (en) * 1997-04-11 2003-01-31 Searle & Co ANTI-INTEGRINE ANTIBODIES ANTI-INTEGRINA AVB3
US6596276B1 (en) * 1997-09-30 2003-07-22 Beth Israel Deaconess Medical Center Method for inhibiting tumor angiogenesis in a living subject
US6172256B1 (en) * 1998-03-04 2001-01-09 G.D. Searle & Co. Chiral-β-amino acid compounds and derivatives thereof
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
US6524553B2 (en) * 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
ES2241313T3 (en) 1998-03-31 2005-10-16 Bristol-Myers Squibb Pharma Company PHARMACEUTICAL COMPOUNDS FOR THE FORMATION OF IMAGES OF ANGIOGENIC DISORDERS.
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7387779B2 (en) * 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) * 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
WO2000002584A2 (en) 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
RU2167425C2 (en) * 1998-07-17 2001-05-20 Малышев Игорь Юрьевич Method for identifying proteins
US6164281A (en) * 1998-07-20 2000-12-26 Zhao; Iris Ginron Method of making and/or treating diseases characterized by neovascularization
WO2000009143A1 (en) * 1998-08-13 2000-02-24 G.D. Searle & Co. Multivalent avb3 and metastasis-associated receptor ligands
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US7176289B1 (en) 1998-09-11 2007-02-13 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US20030202977A1 (en) * 1998-11-16 2003-10-30 New York University Treatment of osteoarthritis
US6235877B1 (en) * 1999-08-04 2001-05-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
EP1135153B1 (en) * 1998-11-20 2005-04-27 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
US6339062B1 (en) * 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) * 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
NZ511677A (en) 1998-12-18 2003-10-31 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
TR200101757T2 (en) * 1998-12-18 2001-12-21 Dupont Pharmaceuticais Company Vitronectin receptor antagonist pharmaceuticals
CA2356748A1 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
DK1156823T3 (en) * 1999-02-12 2009-01-19 Scripps Research Inst Methods for treating tumors and metastases using a combination of anti-angiogenic therapies and immunotherapies
WO2000059532A1 (en) * 1999-04-01 2000-10-12 Biostratum, Inc. The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
AU4982200A (en) * 1999-05-06 2000-11-21 Burnham Institute, The Antiangiogenic endostatin peptides, endostatin variants and methods of use
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6685914B1 (en) 1999-09-13 2004-02-03 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
US20080038274A1 (en) * 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
WO2001021196A1 (en) * 1999-09-23 2001-03-29 The Scripps Research Institute Method and compositions for inhibiting adhesion formation
ATE363290T1 (en) * 1999-10-04 2007-06-15 Novartis Vaccines & Diagnostic CD40 ANTAGONIST FOR THE TREATMENT OF PSORIASIS
ATE553782T1 (en) 1999-12-22 2012-05-15 Scripps Research Inst PHARMACEUTICAL COMPOSITIONS CONTAINING SRC AND/OR YES AND THEIR USE
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
KR100767000B1 (en) * 2000-02-03 2007-10-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Integrin expression inhibitors
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
AU2001236909A1 (en) * 2000-02-11 2001-08-20 Duke University Method of treating disorders of the eye
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6835806B2 (en) 2000-04-03 2004-12-28 Phoenix Pharmaceuticals, Inc. Cell growth regulation system
PT1272507E (en) 2000-04-12 2005-11-30 Amersham Health As DERIVATIVES OF PEPTIDES FOR CONNECTION TO INTEGRINA
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20030104573A1 (en) * 2000-09-11 2003-06-05 Shimkets Richard A. Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
NO20004795D0 (en) 2000-09-26 2000-09-26 Nycomed Imaging As Peptide-based compounds
EP1363653A4 (en) * 2000-10-02 2004-12-22 Scripps Research Inst Methods and compositions for enhancing angiogenesis
US6632835B2 (en) 2001-02-22 2003-10-14 Nanodesign Inc. Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
DE10109136A1 (en) * 2001-02-26 2002-09-12 Cytotools Gmbh Using inhibitor of thrombospondin-1 interaction for promoting wound healing, also for treating living skin replacements, inhibits apoptosis of wound-repair cells
CN1507354A (en) * 2001-03-02 2004-06-23 ͨ��ҽ�ƹ�˾ Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
AU2002316855B2 (en) 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
SE0101854L (en) * 2001-05-28 2002-11-29 Bioneris Ab Use of a compound with a negatively charged region of groups for the treatment of restenosis.
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
EP1414491A4 (en) * 2001-07-09 2005-07-06 Elan Pharm Inc Methods of inhibiting amyloid toxicity
MXPA04000173A (en) 2001-07-10 2004-03-18 Amersham Health As Peptide-based compounds.
WO2003012122A2 (en) * 2001-07-27 2003-02-13 University Of Kansas Medical Center Crystallized structure of type iv collagen nc1 domain hexamer
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
JP2005501887A (en) * 2001-09-05 2005-01-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション Compositions and uses thereof in the treatment of cancer
KR20100054884A (en) 2001-10-22 2010-05-25 더 스크립스 리서치 인스티튜트 Antibody targeting compounds
PL371281A1 (en) * 2002-02-14 2005-06-13 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases
US20050106136A1 (en) * 2002-02-15 2005-05-19 Richard Brunner 7s immunoglobulin for treatment of choroidal neovascularisation
WO2003075741A2 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
JP2005535572A (en) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド Recombinant anti-interleukin-9 antibody
DK2283868T3 (en) 2002-07-15 2016-04-25 Univ Texas PEPTIDES BINDING TO PHOSPHATIDYLETHANOLAMINE AND ITS USE IN TREATING VIRUS INFECTIONS AND CANCER
GB0217018D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 1
EA008683B1 (en) * 2002-07-23 2007-06-29 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
AU2003295644A1 (en) * 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) * 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
CA2514653A1 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
AU2004209457A1 (en) 2003-02-06 2004-08-19 Tripep Ab Antigen/antibody or ligand/receptor glycosylated specificity exchangers
US7335359B2 (en) * 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
US20040224914A1 (en) * 2003-04-18 2004-11-11 The University Of British Columbia Method for treatment of angiogenic disorders
JP2007525187A (en) * 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド Intron fusion proteins and methods for identifying and using the same
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
JP2006526641A (en) * 2003-05-30 2006-11-24 セントカー・インコーポレーテツド Method for inhibiting tumor growth using anti-tissue factor antibody
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
WO2004113361A2 (en) * 2003-06-20 2004-12-29 The Regents Of The University Of California Novel prokineticin receptor isoforms and methods of use
US8415364B2 (en) * 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
PL1718283T3 (en) 2004-01-22 2013-08-30 Univ Miami Topical co-enzyme q10 formulations and methods of use
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
EP1720910A4 (en) * 2004-02-17 2007-11-21 Cancervax Corp Method and composition for angiogenesis inhibition
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
JP4928443B2 (en) * 2004-05-07 2012-05-09 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods for enhancing or inhibiting insulin-like growth factor I
WO2005113596A2 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
US7528106B2 (en) 2004-06-04 2009-05-05 The Scripps Research Institute Compositions and methods for treatment of neovascular diseases
WO2006012415A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
WO2006017619A2 (en) * 2004-08-06 2006-02-16 The Regents Of The University Of California Receptor-binding cyclic peptides and methods of use
CA2577329A1 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
KR100679100B1 (en) * 2004-10-29 2007-02-06 엘지.필립스 엘시디 주식회사 Liquid Crystal Display Panel Of Horizontal Electronic Fileld Applying Type and Method of Fabricating the same
CN101124243A (en) * 2004-12-23 2008-02-13 莫尔梅德股份有限公司 Conjugation product
US20080317752A1 (en) * 2005-04-18 2008-12-25 Sloan-Kettering Institute For Cancer Research Inhibition of Tumorigenesis by Inhibition of a6b4 Integrin
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
US20060286148A1 (en) * 2005-05-18 2006-12-21 Ppd, Inc. Method of forming implants
EP1899376A2 (en) 2005-06-16 2008-03-19 The Feinstein Institute for Medical Research Antibodies against hmgb1 and fragments thereof
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
AU2006283174A1 (en) * 2005-08-24 2007-03-01 Cell-Matrix, Inc. Combination therapies for inhibiting integrin-extracellular matrix interactions
CA2637387A1 (en) 2006-01-18 2007-07-26 Simon Goodman Specific therapy using integrin ligands for treating cancer
KR101201886B1 (en) 2006-01-19 2012-11-15 아이진 주식회사 Pharmaceutical composition for treating vascular-related diseases comprising peptide
NZ574093A (en) * 2006-06-12 2011-03-31 Symphogen As Pan-cell surface receptor- specific therapeutics
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
LT2068889T (en) 2006-08-10 2020-02-10 Roy C. Levitt Anakinra for use in the treatment of bronchiolitis obliterans syndrome
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
DK2025685T3 (en) * 2007-08-15 2013-09-02 Canadian Blood Services Monoclonal antibodies against BETA3 integrins.
US20100278801A1 (en) * 2007-10-16 2010-11-04 Shepard H Michael Compositions comprising optimized her1 and her3 multimers and methods of use thereof
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
EP2633864A1 (en) 2008-07-25 2013-09-04 The Regents of the University of Colorado Clip inhibitors and methods of modulating immune function
WO2010051531A1 (en) 2008-10-31 2010-05-06 University Of Louisville Reserch Foundation, Inc. Olfactory epithelial-derived stem cells and methods of use therefor
US20110256055A1 (en) 2008-12-23 2011-10-20 Ge Healthcare Limited Application of 99mtc peptide-based compound as a bone marrow imaging agent
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
US20120130146A1 (en) 2009-05-25 2012-05-24 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
FR2949782B1 (en) * 2009-09-04 2015-10-16 Isp Investments Inc TRANSGLUTAMINASE ACTIVATOR PEPTIDE AND COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING SAME.
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
CA2805338A1 (en) 2010-07-16 2012-01-19 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
CN103347540B (en) 2011-02-11 2016-05-25 默克专利股份公司 Be used for the treatment of anti-α-v alpha 2 integrin antibodies of prostate cancer
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
RU2531502C2 (en) * 2011-08-09 2014-10-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Method for increasing angiogenic activity of stromal cells of fatty tissue
RU2481115C1 (en) * 2011-10-13 2013-05-10 Общество с ограниченной ответственностью Научно-Производственное Объединение "Тюменькриобанк" Cellgel wound healing product, method for preparing it and method for healing of wounds of various aethiologies by prepared product
US9775803B2 (en) 2011-10-19 2017-10-03 Samsung Electronics Co., Ltd. Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
KR20150041619A (en) * 2012-06-07 2015-04-16 디씨비-유에스에이 엘엘씨 Modified fibronectin fragments or variants and uses thereof
JP2015533117A (en) 2012-08-31 2015-11-19 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Monoclonal antibody for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
WO2014063012A1 (en) 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
WO2014087429A1 (en) 2012-12-07 2014-06-12 Council Of Scientific & Industrial Research Histidinylated cationic amphiphiles, process for preparation thereof and their liposomal formulation
ES2872403T3 (en) * 2013-03-14 2021-11-02 Childrens Medical Center Psap peptide for the treatment of cancers expressing CD36
JP7034914B2 (en) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-α-v integrin antibody for the treatment of fibrosis and / or fibrotic disease
EP3576726A1 (en) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
MX2019011717A (en) 2017-03-31 2019-12-16 Univ California Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers.
KR102171433B1 (en) * 2018-05-25 2020-11-02 고려대학교 산학협력단 Substance p peptide-fixed fibrin gel for tissue regeneration and preparation method thereof
US20220133913A1 (en) * 2019-07-24 2022-05-05 Korea Basic Science Institute SINGLE DOMAIN ANTIBODY TARGETING aVB3 INTEGRIN
CN114144181A (en) * 2019-08-02 2022-03-04 加利福尼亚大学董事会 Compositions and methods for targeting and killing alpha-v beta-3 (alpha v beta 3) positive Cancer Stem Cells (CSCs) and treating drug-resistant and metastatic cancers
KR20230078657A (en) 2020-08-27 2023-06-02 에노시 테라퓨틱스 코퍼레이션 Methods and compositions for treating autoimmune diseases and cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
WO1989005155A1 (en) * 1987-11-19 1989-06-15 Scripps Clinic And Research Foundation Monoclonal antibody against the rgd-directed adhesion receptor of endothelial cells
JPH01169343A (en) 1987-12-25 1989-07-04 Nippon Sheet Glass Co Ltd Cut defect detector for glass plate
IE64346B1 (en) * 1988-01-19 1995-07-26 Moses Judah Folkman Growth inhibiting agent and the use thereof
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5575815A (en) 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5770564A (en) 1989-06-16 1998-06-23 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5262520A (en) * 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5202352A (en) * 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance
CA2048078A1 (en) * 1990-11-15 1992-05-16 Wolfgang A. Wrasidlo Chemical modification of antibodies for creation of immunoconjugates
LU91067I2 (en) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
AU680411B2 (en) 1992-04-03 1997-07-31 Genentech Inc. Antibodies to alphavbeta3 integrin
SK57693A3 (en) * 1992-06-18 1994-07-06 Merck Patent Gmbh Linear peptides and pharmaceutical agents on their base
UA43823C2 (en) * 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг PHARMACEUTICAL COMPOSITION FOR INTEGRIN INHIBITION <font face = "Symbol"> a </font> <sub> V </sub> <font face = "Symbol"> b </font> <sub> 3 </sub> cell adhesion mammal WAY treatment and prevention of diseases associated with cell adhesion DISORDERS, METHOD FOR BINDING LOCK integrin fibrinogen, a composition for wound healing
EP0669988B2 (en) 1992-10-29 2009-07-08 The Australian National University Angiogenesis inhibitory antibodies
AU6235294A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
DE4310643A1 (en) 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclic adhesion inhibitors
CN1230201C (en) † 1993-11-05 2005-12-07 森特克公司 Blood-platelet specific mosaic immune globulin and its using method
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE19534177A1 (en) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclic adhesion inhibitors
DE19538741A1 (en) 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptide derivatives

Also Published As

Publication number Publication date
FI963692A (en) 1996-09-18
ATE490784T1 (en) 2010-12-15
HU9602541D0 (en) 1996-11-28
NZ511293A (en) 2005-06-24
FI963692A0 (en) 1996-09-18
AU1995295A (en) 1995-10-09
MX9604145A (en) 1998-05-31
US7482007B2 (en) 2009-01-27
DK1410807T3 (en) 2011-03-07
ES2355074T3 (en) 2011-03-22
SK284586B6 (en) 2005-07-01
US20040265317A1 (en) 2004-12-30
ES2211901T5 (en) 2011-12-12
JP4758281B2 (en) 2011-08-24
DE69532279T2 (en) 2004-09-16
EP0754059B2 (en) 2011-08-24
HUT76086A (en) 1997-06-30
US5766591A (en) 1998-06-16
EP0754059A4 (en) 1997-07-30
NO963894L (en) 1996-11-18
DK0754059T3 (en) 2004-04-13
DE69532279T3 (en) 2011-11-17
SK119096A3 (en) 1997-07-09
US20050002936A1 (en) 2005-01-06
US6887473B1 (en) 2005-05-03
ATE255907T1 (en) 2003-12-15
ES2376850T3 (en) 2012-03-20
FI121916B (en) 2011-06-15
SI0754059T1 (en) 2004-06-30
HU221988B1 (en) 2003-03-28
PT1468695E (en) 2012-02-09
EP0754059A1 (en) 1997-01-22
CZ271196A3 (en) 1998-01-14
DK1468695T3 (en) 2012-02-27
SI0754059T2 (en) 2011-12-30
DE69536128D1 (en) 2011-01-20
NO322441B1 (en) 2006-10-09
NO963894D0 (en) 1996-09-17
HK1013960A1 (en) 1999-09-17
JPH10500398A (en) 1998-01-13
CN1151120A (en) 1997-06-04
US20040258691A1 (en) 2004-12-23
US7329406B2 (en) 2008-02-12
WO1995025543A1 (en) 1995-09-28
KR970701564A (en) 1997-04-12
US7595051B2 (en) 2009-09-29
CA2184493C (en) 2010-05-11
AU709645B2 (en) 1999-09-02
EP1410807B1 (en) 2010-12-08
NZ283022A (en) 2001-05-25
ATE534403T1 (en) 2011-12-15
KR100327081B1 (en) 2002-10-18
JP4268222B2 (en) 2009-05-27
US20080175840A1 (en) 2008-07-24
EP0754059B1 (en) 2003-12-10
ES2211901T3 (en) 2004-07-16
US5753230A (en) 1998-05-19
EP1468695A1 (en) 2004-10-20
EP1468695B1 (en) 2011-11-23
CZ294650B6 (en) 2005-02-16
NZ548433A (en) 2008-04-30
UA44729C2 (en) 2002-03-15
US7354586B2 (en) 2008-04-08
CN1161152C (en) 2004-08-11
PT754059E (en) 2004-04-30
RU2162712C2 (en) 2001-02-10
ZA952214B (en) 1996-02-08
JP2006273862A (en) 2006-10-12
EP1410807A1 (en) 2004-04-21
DE69532279D1 (en) 2004-01-22
DK0754059T4 (en) 2011-09-19

Similar Documents

Publication Publication Date Title
CA2184493A1 (en) Methods and compositions useful for inhibition of angiogenesis
RU96120204A (en) METHODS AND COMPOSITIONS SUITABLE FOR INHIBITING ANGIOGENESIS
CA2256543A1 (en) Methods and compositions useful for inhibition of angiogenesis
RU98123833A (en) METHODS AND COMPOSITIONS USED TO INHIBIT ANGIOGENESIS
AP660A (en) A method of treatment of parasitic infection using IgE antagonists.
RU98123834A (en) METHODS AND COMPOSITIONS USED TO INHIBIT αvβ5-MEDIATED ANGI GENESIS
CA2754102A1 (en) Monoclonal antibodies and compositions comprising such useful for inhibition of .alpha.v.beta.5 mediated angiogenesis
US5786333A (en) Platelet aggregation inhibitors
ATE258444T1 (en) THERAPEUTIC CHEMOKINE RECEPTOR ANTAGONISTS
EP2085095B1 (en) Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
US5667781A (en) Enhanced inhibition of tumor cell proliferation using a combination of two monoclonal antibodies to the human transferrin receptor
EP2522676A2 (en) Disintegrin variants and pharmaceutical uses thereof
WO2004066932A2 (en) Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
CA2343579A1 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CA2253239C (en) Antibodies against interferon alpha/beta receptor
JP2001072589A (en) Carcinostatic agent
JP2005506345A5 (en)
WO2019173902A1 (en) Cd47 blockade therapy with cd38 antibody
Bruck et al. Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice.
CA2090401A1 (en) Method of treating viral infection
US5725851A (en) Method and compositions for treating injury
TW470646B (en) Pharmaceutical composition for use in the treatment of conditions requiring inhibition of vascular smooth muscle cell migration comprising R(+) isomer of amlodipine
US6537551B2 (en) Anti-tumor agent comprising salmosin as an active ingredient
AU657015B2 (en) The use of d-fenfluramine and fenfluramine compounds in the treatment of hypertension in insulin-resistant subjects
Boyle et al. Regulation of CS1 fibronectin expression and function by IL-1 in endothelial cells

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150309